Payment overview · 2025
General Payments
$97.28
5 reported records · 5 companies
Healthcare provider profile · identity verified
Kimberly Hinman
Allopathic & Osteopathic Physicians|Family Medicine · ABILENE, KS · NPI 1336644152
Verified facts
What the public records show
CMS Open Payments records show Kimberly Hinman received $97.28 in general payments during 2025 across 5 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.12 | 29.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.75 | 19.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.59 | 19.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.30 | 16.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.52 | 14.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $97.28 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.12 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 563 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 465 | 74 |
| Gabapentin | Gabapentin | 320 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 54 |
| Losartan Potassium | Losartan Potassium | 267 | 51 |
| Lisinopril | Lisinopril | 254 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 229 | 43 |
| Omeprazole | Omeprazole | 225 | 47 |
| Furosemide | Furosemide | 212 | 38 |
| Potassium Chloride | Potassium Chloride | 183 | 30 |
| Simvastatin | Simvastatin | 182 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 35 |
| Trazodone Hcl | Trazodone Hcl | 168 | 27 |
| Sertraline Hcl | Sertraline Hcl | 163 | 24 |
| Mirtazapine | Mirtazapine | 150 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 28 |
| Donepezil Hcl | Donepezil Hcl | 142 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 33 |
| Metformin Hcl | Metformin Hcl | 122 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 25 |
| Xarelto | Rivaroxaban | 106 | 13 |
| Famotidine | Famotidine | 105 | 24 |
| Warfarin Sodium | Warfarin Sodium | 99 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 20 |
| Eliquis | Apixaban | 86 | 12 |
| Montelukast Sodium | Montelukast Sodium | 86 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 24 |
| Pregabalin | Pregabalin | 77 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 13 |
| Tramadol Hcl | Tramadol Hcl | 76 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 11 |
| Aripiprazole | Aripiprazole | 72 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 16 |
| Carvedilol | Carvedilol | 66 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Spironolactone | Spironolactone | 66 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | suppressed |
| Jardiance | Empagliflozin | 61 | suppressed |
| Memantine Hcl | Memantine Hcl | 61 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 12 |
| Alprazolam | Alprazolam | 56 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 16 |
| Atenolol | Atenolol | 53 | 12 |
| Meloxicam | Meloxicam | 53 | 23 |
| Ozempic | Semaglutide | 53 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 51 | suppressed |
| Allopurinol | Allopurinol | 48 | 12 |
| Bumetanide | Bumetanide | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | suppressed |
| Lorazepam | Lorazepam | 44 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 39 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | 11 |
| Digoxin | Digoxin | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Prednisone | Prednisone | 27 | 22 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 26 |
| Lidocaine | Lidocaine | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Nystatin | Nystatin | 25 | 12 |
| Topiramate | Topiramate | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Olanzapine | Olanzapine | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 14 |
| Cephalexin | Cephalexin | 15 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Primidone | Primidone | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Liraglutide | Liraglutide | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $97.28 · 5 records | Otsuka America Pharmaceutical, Inc. | Auvelity, BEXSERO, EVENITY, LEQVIO, PEDIARIX, PENMENVY, REXULTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error